|Bid||7.50 x 3000|
|Ask||7.55 x 1800|
|Day's range||7.55 - 8.04|
|52-week range||3.75 - 16.86|
|Beta (3Y monthly)||4.16|
|PE ratio (TTM)||25.59|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
These two marijuana stocks reported very different results last quarter. Plus, how Abbott's challenging Dexcom in diabetes, and what's next for Bristol-Myers following its Celgene acquisition.
LEAMINGTON, ON , April 18, 2019 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APHA and NYSE: APHA) today announced that its German subsidiary Aphria Deutschland GmbH ("Aphria Germany") has secured the previously announced license for the domestic cultivation of medical cannabis from the German Federal Institute for Drugs and Medical Devices ("BfArM"), following the conclusion of a mandatory 10-day standstill period for public contracts. Aphria was granted a cultivation license for four of the nine total lots awarded by BfArM and is awaiting the completion of the tender process for the four remaining lots under review, one of which was provisionally awarded to Aphria Germany.
Canopy Growth will probably purchase the rights to buy Acreage Holdings to tap the growing potential of the U.S. marijuana market. This should bolster the ETF MJ.
LEAMINGTON, ON , April 17, 2019 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APHA and NYSE: APHA) today announced the pricing of US$300 million aggregate principal amount of 5.25% convertible senior notes due 2024 (the "notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the U.S. Securities Act of 1933, as amended (the "Act"), and outside the United States to non-U.S. persons in compliance with Regulation S under the Act. Aphria also granted the initial purchasers of the notes an option, exercisable within a 30-day period, to purchase up to an additional US$50 million aggregate principal amount of notes. The sale of the notes to the initial purchasers is expected to settle on April 23, 2019 , subject to the satisfaction of customary closing conditions.
Canopy Growth's next quarterly update might not be nearly as rosy as its last one. And the situation could be even worse for other marijuana producers.
LEAMINGTON, ON , April 16, 2019 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APHA and NYSE: APHA), a leading global cannabis company, today announced that it proposes to offer pursuant to a private placement US$300 million aggregate principal amount of convertible senior notes due 2024 (the "notes"), subject to market conditions and other factors. Aphria also intends to grant to the initial purchasers of the notes an option, exercisable within 30-day period, to purchase up to an additional US$45 million aggregate principal amount of notes. The notes are to be offered and sold to qualified institutional buyers pursuant to Rule 144A under the U.S. Securities Act of 1933, as amended (the "Act"), and outside the United States to non-U.S. persons in compliance with Regulation S under the Act.
Could the reasons behind Aphria's dismal Q3 results bite Aurora Cannabis, Canopy Growth, and others in their next quarterly updates?
STOCKSTOWATCHTODAY BLOG Three numbers to start your day: 3.8% is how far shares of (GS) fell Monday —after the bank reported first-quarter earnings. The bank’s profits were better than what Wall Street analysts had expected.
While many cannabis stocks have been white hot this year, not all are seeing green. In fact, as Cowen & Co. notes, there has been a spate of profit-taking recently, as investors take a more cautious stance ahead of first-quarter earnings reports. While many marijuana stocks have notched big gains in 2019, volatility is the name of the game.
Cannabis stocks were a sea of red, weighed down by Aphria after it swung to a wide loss in the third quarter that outweighed a surge in revenue.
The Canadian marijuana grower reported an adjusted loss of 20 Canadian cents per share, far steeper than Wall Street had been expecting.
High Tide Announces Licences and Authorizations from AGCO to Open Canna Cabana-Branded Stores in Hamilton and Sudbury
LEAMINGTON, ON , April 15, 2019 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APHA and NYSE: APHA) today announced that it has entered into a series of transactions that will accelerate the expiry date to April 25, 2019 for the previously announced take-over bid by Green Growth Brands Inc. ("GGB") and will terminate the arrangements with GA Opportunities Corp. ("GAOC") for consideration of $89.0 million . Irwin D. Simon , Aphria's Chairman and Interim Chief Executive Officer stated, "We are very pleased to move forward with this favorable resolution as we continue to focus on the long-term growth of our leading cannabis business. Aphria has entered into a shortened deposit period agreement with GGB to facilitate the acceleration of the expiry of GGB's offer to purchase all of the issued and outstanding shares of Aphria (the "GGB Offer").
Canadian marijuana company Aphria is scheduled to report fiscal third-quarter earnings on April 15, its first report under a new CEO.